Intravenous Busulfan-Based Myeloablative Conditioning Regimens Prior to Hematopoietic Cell Transplantation for Hematologic Malignancies
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Aug 01, 2016
- Source ID
- 10.1016/j.bbmt.2016.04.013
Entities
People
- Andrew Artz
- Christopher Bredeson
- Hugo F. Fernandez
- Jayesh Mehta
- Jeanne Burkart
- Jennifer Le-Rademacher
- John DiPersio
- Marcelo C Pasquini
- Masaru Kamishohara
- Ronald Sobecks
- Shin Mineishi
- Voravit Ratanatharathorn
- Xiaochun Zhu
- Yuki Nakamura
Organizations
- Alexion Pharmaceuticals
- Amgen
- Bristol-Myers Squibb
- Celgene
- Chiron Corporation
- Elevance Health, Inc.
- Fred Hutchinson Cancer Center
- Genzyme
- Gilead Sciences
- Health Research
- Health Resources and Services Administration
- HistoGenetics (United States)
- Incyte
- Jazz Pharmaceuticals
- Leukemia & Lymphoma Society
- Medical College of Wisconsin
- Merck & Co.
- Miltenyi Biotec
- National Cancer Institute
- National Heart, Lung, and Blood Institute
- National Institute of Allergy and Infectious Diseases
- National Marrow Donor Program
- Office of Naval Research
- Onyx Pharmaceuticals
- Otsuka (United States)
- Otsuka Pharmaceutical
- Pharmacyclics
- Roche (United States)
- Roswell Park Comprehensive Cancer Center
- Sanofi-Aventis
- Seagen
- Sigma-Tau Pharmaceuticals (United States)
- Spectrum Pharmaceuticals
- St. Baldrick's Foundation
- Swedish Orphan Biovitrum
- United States Public Health Service
- University of Minnesota